Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.21
Dollar change
+0.17
Percentage change
8.33
%
IndexRUT P/E- EPS (ttm)-0.45 Insider Own10.77% Shs Outstand138.13M Perf Week3.76%
Market Cap310.39M Forward P/E- EPS next Y-0.15 Insider Trans0.58% Shs Float125.33M Perf Month-26.82%
Income-62.26M PEG- EPS next Q-0.11 Inst Own41.20% Short Float7.37% Perf Quarter-2.86%
Sales163.91M P/S1.89 EPS this Y23.17% Inst Trans-3.18% Short Ratio3.96 Perf Half Y16.32%
Book/sh-0.05 P/B- EPS next Y57.78% ROA-18.17% Short Interest9.24M Perf Year66.17%
Cash/sh0.52 P/C4.28 EPS next 5Y- ROE-324.20% 52W Range1.26 - 3.26 Perf YTD-5.96%
Dividend Est.- P/FCF- EPS past 5Y38.13% ROI-28.44% 52W High-32.21% Beta1.62
Dividend TTM- Quick Ratio1.23 Sales past 5Y195.35% Gross Margin75.91% 52W Low75.40% ATR (14)0.16
Dividend Ex-Date- Current Ratio1.64 EPS Y/Y TTM35.22% Oper. Margin-26.85% RSI (14)41.85 Volatility5.70% 7.09%
Employees377 Debt/Eq- Sales Y/Y TTM48.68% Profit Margin-37.98% Recom1.00 Target Price4.75
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-1.89% Payout- Rel Volume1.38 Prev Close2.04
Sales Surprise-1.53% EPS Surprise-16.96% Sales Q/Q33.93% EarningsMar 06 BMO Avg Volume2.33M Price2.21
SMA20-7.04% SMA50-15.11% SMA200-2.77% Trades Volume3,220,076 Change8.33%
Date Action Analyst Rating Change Price Target Change
Mar-28-24Initiated Oppenheimer Outperform $5
Aug-28-23Initiated Craig Hallum Buy $4.50
Oct-21-22Initiated Jefferies Buy $4
Apr-28-22Initiated Craig Hallum Buy $6.50
Nov-17-21Initiated SVB Leerink Outperform $6
Oct-29-21Initiated H.C. Wainwright Buy $4
Apr-07-21Resumed RBC Capital Mkts Outperform $11
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
12:52PM
08:15AM
07:17AM Loading…
07:17AM
07:02AM
07:00AM
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
07:00AM Loading…
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
01:53AM
Nov-09-23 11:30AM
08:10AM
07:17AM
07:00AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
04:05PM Loading…
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
09:15AM
07:13AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-29-23 04:19PM
Jun-22-23 01:50PM
Jun-21-23 07:00AM
Jun-19-23 12:58PM
Jun-01-23 07:00AM
May-09-23 11:33PM
07:25AM
07:00AM
May-08-23 06:37AM
May-02-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 06:25AM
Apr-06-23 08:21AM
Apr-05-23 01:18PM
Mar-30-23 07:00AM
Mar-29-23 04:05PM
Mar-08-23 11:52PM
06:00AM
Feb-23-23 07:00AM
Feb-02-23 07:00AM
Jan-30-23 07:00AM
Jan-05-23 04:03PM
07:00AM
Dec-31-22 09:33AM
Dec-15-22 07:00AM
Nov-24-22 10:56AM
Nov-23-22 06:00AM
Nov-16-22 09:53AM
Nov-09-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Nov-01-22 07:00AM
Oct-20-22 10:28AM
06:00AM
Oct-06-22 06:07AM
Sep-05-22 12:00PM
Aug-10-22 07:00AM
Aug-03-22 07:30AM
Aug-01-22 07:30AM
Jul-24-22 10:03AM
Jun-09-22 07:09AM
May-27-22 09:38AM
May-12-22 04:02PM
May-11-22 07:00AM
May-04-22 08:00AM
Mar-23-22 10:34AM
Mar-16-22 07:00AM
Mar-10-22 07:00AM
06:55AM
Mar-04-22 07:00AM
Mar-01-22 03:00PM
Feb-09-22 07:00AM
Jan-31-22 07:00AM
Jan-13-22 08:55AM
Jan-07-22 10:13AM
Jan-06-22 07:00AM
Jan-03-22 07:00AM
Dec-31-21 03:10PM
01:42PM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON JOHNDirectorMar 18 '24Option Exercise1.99215,600429,044751,412Mar 18 05:32 PM
Schmid John P.DirectorMar 14 '24Buy2.164,5009,72011,000Mar 14 09:03 PM
SHERMAN JEFFREY WDirectorNov 27 '23Buy1.875,40010,0985,400Nov 29 04:09 PM
Pieper StevenSee RemarksNov 20 '23Buy1.9528,00054,6001,176,912Nov 21 04:16 PM
HALKUFF DAWNDirectorNov 20 '23Buy1.845,4109,9545,410Nov 21 04:20 PM
Shannon John Patrick JrSee RemarksNov 17 '23Buy1.6430,76950,4001,408,575Nov 17 05:58 PM
Schmid John P.DirectorNov 16 '23Buy1.516,5009,8156,500Nov 17 06:35 PM
PERSKY MARLADirectorNov 14 '23Buy1.586,37010,0586,370Nov 15 04:13 PM
Edick Paul RSee RemarksAug 09 '23Buy2.3810,00023,7942,288,064Aug 09 06:57 PM